肿瘤细胞治疗研究
英文原题：Recent advances in adoptive cell therapy for cancer immunotherapy.
过继性细胞疗法（ACT）是肿瘤免疫治疗的一个关键方向，近年来取得了显著进展。
过继细胞疗法（ACT）是肿瘤免疫治疗的重要方向，近年来取得显著进展。本文系统综述ACT的现状和未来趋势，涵盖淋巴因子激活的杀伤细胞（LAK）、TIL（肿瘤浸润淋巴细胞）、细胞因子诱导的杀伤细胞（CIK）、树突状细胞（DC）、T细胞受体改造T细胞（TCR-T）、CAR-T 细胞、自然杀伤（NK）细胞、CAR改造NK细胞（CAR-NK）以及新兴的CAR-M。文章重点介绍新兴技术策略，包括通用型CAR结构优化、诱导多能干细胞（iPSC）来源细胞产品、多功能CAR设计及AI辅助抗原筛选。还比较不同细胞疗法在抗原特异性、疗效持久性、安全性及临床应用挑战方面的差异。本文的核心贡献是综合近期研究进展，并提出应对ACT中肿瘤异质性、抗原逃逸、细胞持久性和治疗安全性问题的策略，为未来个体化和精准细胞疗法提供参考。
Adoptive cell therapy (ACT), a key direction in tumor immunotherapy, has achieved remarkable progress in recent years. This paper systematically reviews the current status and future trends of ACT, covering lymphokine-activated killer cells (LAK), tumor-infiltrating lymphocytes (TIL), cytokine-induced killer cells (CIK), dendritic cells (DC), T cell receptor-modified T cells (TCR-T), chimeric antigen receptor T cells (CAR-T), natural killer (NK) cells, chimeric antigen receptor-modified NK cells (CAR-NK), and the emerging CAR-M. The paper focuses on emerging technological approaches, including universal CAR structural optimization, iPSC-derived cell products, multifunctional CAR design, and AI-assisted antigen screening. It also compares differences among various cell therapies in antigen specificity, efficacy persistence, safety, and clinical application challenges. The core contribution of this paper lies in synthesizing recent research advances to propose strategies for addressing tumor heterogeneity, antigen escape, cell persistence, and therapeutic safety in ACT. This provides a reference for future personalized and precision cell therapy approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。
